Challenges Seen With Novel Agents in Multiple Myeloma
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
At the start of her practice, lenalidomide (Revlimid) and bortezomib (Velcade) were the only 2 novel agents available for patients with myeloma. Now, there are monoclonal antibodies, checkpoint inhibitors, CAR T cells, and many more.
With so many novel and targeted agents appearing in the treatment landscape, it is hard to keep up with all of the latest data for these drugs. In most cases, there is still not enough information available on the overall survival or progression-free survival with these drugs, Madduri says.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
